Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr- deficient mice
Science Translational Medicine · 28.05.2025 · 17 (800)
DOI: 10.1126/scitranslmed.adj8192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 28.05.2025. Verfasst von Doriane Henry und 10 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France. Hauptthemen laut MEDLINE: PPAR alpha, Atherosclerosis, Hepatocytes, Receptors, LDL. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 90 Literaturangaben.
Abstract (Originalsprache)
Atherogenic dyslipidemia and chronic inflammation appear strongly associated with residual cardiovascular disease (CVD) risk. Peroxisome proliferator–activated receptor α (PPARα) agonists, which exert both triglyceride-lowering and anti-inflammatory properties, are potential therapeutic candidates to target residual CVD risk. However, CVD outcome studies with these drugs have yielded mixed results for currently unclear reasons. In this study, we compared the impact of hepatocyte anti-inflammatory (transrepression) versus lipid-lowering (transactivation) properties of PPARα agonism on atherosclerosis in Ldlr −/− mice. PPARα agonist treatment reduced aortic atherosclerotic plaque surface in Western diet–fed Ldlr −/− mice expressing in hepatocytes either PPARα WT or a transrepression-selective PPARα mutant (PPARα DISS ), despite the lack of atherogenic dyslipidemia improvement with PPARα DISS . Mechanistically, ligand-activated hepatocyte-specific transrepressive PPARα activity decreased the pro-inflammatory phenotype of hepatocytes, lowered the recruitment of leukocytes in the liver, reduced plasma IL-1β concentrations, and decreased atherosclerotic plaque macrophage content. These findings identify a distal effect of hepatic PPARα on vascular integrity rather linked to its anti-inflammatory activity than its lipid-lowering actions and highlight an essential role of targeting inflammation in CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.
ORCID-Profile: Doriane Henry, Nathalie Hennuyer, Kevin Ory, Audrey Deprince, Philippe Lefebvre, Joel T Haas, Bart Staels, Fanny Lalloyer
Zitieren
APA
Henry, D., Baugé, E., Hennuyer, N., Ory, K., Derudas, B., Vallez, E., Deprince, A., Lefebvre, P., Haas, J. T., Staels, B., & Lalloyer, F. (2025). Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr- deficient mice. Science Translational Medicine, 17(800). https://doi.org/10.1126/scitranslmed.adj8192
Vancouver
Henry D, Baugé E, Hennuyer N, Ory K, Derudas B, Vallez E, et al. Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr- deficient mice. Science Translational Medicine. 2025;17(800). doi:10.1126/scitranslmed.adj8192
BibTeX
@article{Henry2025,
author = {Henry, Doriane and Baugé, Eric and Hennuyer, Nathalie and Ory, Kevin and Derudas, Bruno and Vallez, Emmanuelle and Deprince, Audrey and Lefebvre, Philippe and Haas, Joel T and Staels, Bart and Lalloyer, Fanny},
title = {Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr- deficient mice},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {800},
doi = {10.1126/scitranslmed.adj8192}
}
EUVIMED